Advisors Asset Management Inc. purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 160,138 shares of the company's stock, valued at approximately $22,831,000.
Several other institutional investors and hedge funds have also modified their holdings of the business. Highland Investment Advisors LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at approximately $25,000. Evolution Wealth Management Inc. grew its holdings in shares of Novartis by 552.0% during the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company's stock valued at $26,000 after purchasing an additional 138 shares during the last quarter. Atlatl Advisers LLC bought a new stake in shares of Novartis during the 2nd quarter valued at approximately $26,000. Silicon Valley Capital Partners grew its holdings in shares of Novartis by 519.4% during the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company's stock valued at $30,000 after purchasing an additional 161 shares during the last quarter. Finally, Curry Webb Wealth Management LLC acquired a new position in Novartis during the 3rd quarter worth approximately $28,000. 13.12% of the stock is currently owned by institutional investors.
Recent Novartis Headlines
These are some of the NVS headlines that stood out recently:
- Positive Sentiment: Novartis raised its combined peak-sales forecast for three blockbuster drugs to $18 billion, from $14 billion, strengthening the potential contribution of those medicines to future growth. CNBC article
- Neutral Sentiment: The company still expects annual sales growth of 5% through 2031, indicating continued expansion, though the updated forecast extends the outlook by a year. Reuters article
- Negative Sentiment: The 5% annual growth target is below the previous 5%–6% forecast through 2030. The reduced ambition prompted negative investor reaction and contributed to the decline in Novartis shares. Reuters article Seeking Alpha article
Novartis Price Performance
Novartis stock opened at $150.42 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $287.03 billion, a PE ratio of 18.02, a P/E/G ratio of 2.93 and a beta of 0.40. Novartis AG has a 12 month low of $125.88 and a 12 month high of $170.46. The stock has a 50-day moving average price of $150.45 and a two-hundred day moving average price of $152.75.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, beating analysts' consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $2.25 earnings per share. Analysts expect that Novartis AG will post 9.10 EPS for the current year.
Wall Street Analysts Forecast Growth
NVS has been the subject of several research reports. Deutsche Bank downgraded shares of Novartis from a "hold" rating to a "sell" rating in a research note on Friday, October 30th. Berenberg Bank cut their target price on shares of Novartis from $147.00 to $130.00 and set a "hold" rating on the stock in a research report on Friday, September 11th. Royal Bank Of Canada reaffirmed a "sector perform" rating on shares of Novartis in a research note on Wednesday, October 28th. HSBC upgraded shares of Novartis from a "reduce" rating to a "hold" rating and upped their price target for the stock from $123.00 to $136.00 in a report on Thursday, September 10th. Finally, UBS Group reiterated a "neutral" rating on shares of Novartis in a research note on Wednesday, October 28th. Six equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $152.25.
Check Out Our Latest Analysis on Novartis
Novartis Company Profile
(
Free Report)
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company's medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.